Regeneron Pharmaceuticals Reports on Shareholder Vote Matters

TL;DR

REGN filed an 8-K for a shareholder vote on June 13th.

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders on June 13, 2025. The filing details the company's corporate structure and its principal executive offices located at 777 Old Saw Mill River Road, Tarrytown, New York.

Why It Matters

This filing indicates a formal process of shareholder engagement and voting on corporate matters, which is a standard but important aspect of corporate governance.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not introduce new financial or operational risks.

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — Registrant
• June 18, 2025 (date) — Date of Report
• June 13, 2025 (date) — Date of earliest event reported
• 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (location) — Principal executive offices

FAQ

From the Filing

0001104659-25-060637.txt : 20250618 0001104659-25-060637.hdr.sgml : 20250618 20250618161221 ACCESSION NUMBER: 0001104659-25-060637 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250613 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250618 DATE AS OF CHANGE: 20250618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 251057040 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 8-K 1 tm2518262d1_8k.htm FORM 8-K false 0000872589 2025-06-13 0000872589 2025-06-13 2025-06-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): June 18, 2025 ( June 13, 2025)   REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)   New York (State or other jurisdiction of incorporation)   000-19034   13-3444607 (Commission File Number)   (I.R.S. Employer Identification No.)     777 Old Saw Mill River Road , Tarrytown , New York   10591-6707 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: ( 914 ) 847-7000   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 5.07. Submission of Matters to a Vote of Security Holders.   At the 2025 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) held on June 13, 2025, Regeneron’s shareholders voted on the matters set forth below.   Proposal 1 – Election of Directors   The following nominees for Class I directors were elected to serve until the 2028 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:   Nominee   For